Compound, angiotensin II type 1 receptor antagonist and pharmaceutical composition
AssigneeAlchemedicine, Inc.
InventorKeigo Tanaka
Life of this patent
Estimating the term…
Abstract
A compound represented by the following formula (1): wherein Ar is the following formula (Ar1) or (Ar2): wherein R1 and R2 are each independently an alkyl, a haloalkyl, or a halogen; each R3 is independently an alkyl, a haloalkyl, a halogen, an alkoxy, or a haloalkoxy; and m is an integer of 0 to 3, or a pharmaceutically acceptable salt thereof.
Claims10
A compound represented by the following formula (1):
- wherein
- Ar is the following formula (Ar1) or (Ar2):
- wherein
- R1 and R2 are each independently an alkyl, a haloalkyl, or a halogen;
- each R3 is independently an alkyl, a haloalkyl, a halogen, an alkoxy, or a haloalkoxy;
- and
- m is an integer of 0 to 3,
- or a pharmaceutically acceptable salt thereof.
A method for inhibiting an angiotensin II type 1 receptor, comprising administering to a patient in need thereof an effective amount of the compound represented by the following formula (1),
- wherein
- Ar is the following formula (Ar1) or (Ar2):
- wherein
- R1 and R2 are each independently an alkyl, a haloalkyl, or a halogen;
- each R3 is independently an alkyl, a haloalkyl, a halogen, an alkoxy, or a haloalkoxy;
- and
- m is an integer of 0 to 3,
- or a pharmaceutically acceptable salt thereof.
A method for treating hypertension, cardiac diseases, progression of heart failure after myocardial infarction, renal diseases, vascular hyperplasia after interventions, occlusion after interventions, organ damage after interventions, glaucoma, ocular hypertension, Alzheimer's disease, central nervous system disorders, dementia, hepatic diseases, eosinophilic esophagitis, osteoarthritis of the knee, epidermolysis bullosa or Marfan syndrome, comprising administering to a patient in need thereof an effective amount of a compound represented by the following formula (1), or pharmaceutically acceptable salt thereof,
- wherein
- Ar is the following formula (Ar1) or (Ar2):
- wherein
- R1 and R2 are each independently an alkyl, a haloalkyl, or a halogen;
- each R3 is independently an alkyl, a haloalkyl, a halogen, an alkoxy, or a haloalkoxy;
- and
- m is an integer of 0 to 3,
- or a pharmaceutically acceptable salt thereof.
A compound represented by the following formula (2):
- wherein
- R4 is a leaving group, boronic acid, a boronate ester, or —BF3M1;
- and
- M1 is an alkali metal,
- or a salt thereof.
A compound represented by the following formula (3):
- wherein
- Ar is the following formula (Ar1) or (Ar2):
- wherein
- R1 and R2 are each independently an alkyl, a haloalkyl, or a halogen;
- each R3 is independently an alkyl, a haloalkyl, a halogen, an alkoxy, or a haloalkoxy;
- and
- m is an integer of 0 to 3,
- R5 is a leaving group, or —OR5A;
- R5A is hydrogen or a protective group;
- and
- R6 is hydrogen or a protective group,
- or a salt thereof.
Dependencies are inferred from the claim text.